Clinical Trial Update: Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. [Phase 2]

View source ↗

Summary

Phase 2 trial comparing high-dose interleukin-2 alone versus high-dose interleukin-2 with radiation therapy in metastatic melanoma; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Proleukin (aldesleukin)

Snippet

Sponsor: Providence Health & Services | Conditions: Metastatic Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-11-15